ARKK Holdings of Veracyte (VCYT) - Updated Daily
BioinformaticsGenomics
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 1.45% | $1.64b |
| 🏋🏿♂️Weight Rank In ARKK | 🌏Country |
| 21 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 21 | $14.27 |
| 🎫ARK Ownership Percent | |
| 5.89% | |
| Description | |
|---|---|
| veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. . | |
| Website | |
| https://www.veracyte.com/ |
Other ETFs That Hold VCYT
Research Notes and Commentary for VCYT
No Research Notes Found for VCYT